Can we win the war on obesity with pharmacotherapy?

Expert Review of Clinical Pharmacology

Volumn 9, Issue 10, 2016, Pages 1289-1297

  Gotthardt, Juliet D ^a,b   Bello, Nicholas T ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c the State University of New Jersey   (United States)

Author keywords

Belviq; Contrave; liraglutide; lorcaserin; naltrexone bupropion; Orlistat; phentermine topiramate; Qsymia; Saxenda

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; FENFLURAMINE PLUS PHENTERMINE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CONSTIPATION; DEFECATION URGENCY; DEHYDRATION; DEPRESSED BLOOD PRESSURE; DIETARY SUPPLEMENT; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FIBROMYALGIA; GASTRIC BANDING; GASTRIC BYPASS SURGERY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MURMUR; HEART RATE; HUMAN; INSOMNIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER INJURY; LIVER TOXICITY; LOW CALORY DIET; LOW DRUG DOSE; LUNG EDEMA; MIGRAINE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEATORRHEA; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SURGICAL MORTALITY; TOBACCO DEPENDENCE; UNITED STATES; UPPER ABDOMINAL PAIN; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA;

EID: 84987621962     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1232164     Document Type: Article

References (95)

1. D.M.Lyon, D.M.Dunlop The treatment of obesity:a comparison of the effects of diet and of thyroid extract. QJM. 1932;1(2):331–352.
2. I.N.Love. Thyroid extract in juvenile obesity:a clinical note. JAMA. 1900;XXXIV(16):975–976.
3. M.J.Ree. Thyroid-induced myxoedema. Br Med J. 1962;2(5297):97–99.
4. A.W.Winkler, P.H.Lavietes, C.L.Robbins, et al. Tolerance to oral thyroid and reaction to intravenous thyroxine in subjects without myxedema. J Clin Invest. 1943;22(4):535–544.
5. S.Ramage, A.Farmer, K.A.Eccles, et al. Healthy strategies for successful weight loss and weight maintenance:a systematic review. Appl Physiol Nutr Metab. 2014;39(1):1–20.
6. T.A.Wadden, D.S.West, L.Delahanty, et al. The Look AHEAD study:a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737–752.
7. T.A.Wadden, R.H.Neiberg, R.R.Wing, et al. Four-year weight losses in the Look AHEAD study:factors associated with long-term success. Obesity (Silver Spring). 2011;19(10):1987–1998.
8. L.Lenoir, M.Maillot, A.Guilbot, et al. Primary care weight loss maintenance with behavioral nutrition:an observational study. Obesity (Silver Spring). 2015;23(9):1771–1777.
9. J.G.Thomas, D.S.Bond, S.Phelan, et al. Weight-loss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med. 2014;46(1):17–23.• This paper outlines the guidelines and provided data for the National Weight Control Registry. It provides useful data on responder behaviors and strategies for the long-term maintenance of weight loss.
10. M.A.Fontana, S.D.Wohlgemuth. The surgical treatment of metabolic disease and morbid obesity. Gastroenterol Clin North Am. 2010;39(1):125–133.
11. D.S.Casagrande, D.D.Rosa, D.Umpierre, et al. Incidence of cancer following bariatric surgery:systematic review and meta-analysis. Obes Surg. 2014;24(9):1499–1509.
12. J.A.Largent, J.Vasey, L.Bessonova, et al. Reduction in Framingham risk of cardiovascular disease in obese patients undergoing laparoscopic adjustable gastric banding. Adv Ther. 2013;30(7):684–696.
13. D.Arterburn, A.Bogart, K.J.Coleman, et al. Comparative effectiveness of bariatric surgery vs. nonsurgical treatment of type 2 diabetes among severely obese adults. Obes Res Clin Pract. 2013;7(4):e258–268.
14. A.P.Courcoulas, S.H.Belle, R.H.Neiberg, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for Type 2 diabetes mellitus treatment:a randomized clinical trial. JAMA Surg. 2015;150(10):931–940.
15. R.B.Dorman, C.J.Miller, D.B.Leslie, et al. Risk for hospital readmission following bariatric surgery. PLoS One. 2016;7(3):e32506.
16. M.P.Ostlund, O.Backman, R.Marsk, et al. Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery. JAMA Surg. 2013;148(4):374–377.
17. C.Peterhansel, D.Petroff, G.Klinitzke, et al. Risk of completed suicide after bariatric surgery:a systematic review. Obes Rev. 2013;14(5):369–382.
18. H.A.Tindle, B.Omalu, A.Courcoulas, et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010;123(11):1036–1042.
19. J.A.Bhatti, A.B.Nathens, D.Thiruchelvam, et al. Self-harm emergencies after bariatric surgery:a population-based cohort study. JAMA Surg. 2016;151(3):226–232.
20. FDA. Guidance for industry developing products for weight management. 7533dft, 2007 Jan31; 2007. p. 1–16
21. K.Fujioka. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17(11):1021–1032.
22. J.S.MacDaniels, T.L.Schwartz. Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. Drugs Context. 2016;5:212291.
23. I.Genentech. Xenical:prescribing information. Package Insert. San Francisco (CA); 2015.
24. D.Rucker, R.Padwal, S.K.Li, et al. Long term pharmacotherapy for obesity and overweight:updated meta-analysis. Bmj. 2007;335(7631):1194–1199.•• Meta-analysis of 30 randomized controlled studies of orlistat, sibutramine, and rimonabant. Mean and categorical efficacy is provided for each medication.
25. M.H.Davidson, J.Hauptman, M.DiGirolamo, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat:a randomized controlled trial. Jama. 1999;281(3):235–242.
26. J.S.Torgerson, J.Hauptman, M.N.Boldrin, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study:a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
27. FDA. Questions and Answers:Orlistat and Severe Liver Injury; 2010. Available from: www.fda.gov
28. M.Morris, P.Lane, K.Lee, et al. An integrated analysis of liver safety data from orlistat clinical trials. Obesity Facts. 2012;5(4):485–494.
29. Y.Humayun, K.C.Ball, J.R.Lewin, et al. Acute oxalate nephropathy associated with orlistat. J Nephropathol. 2016;5(2):79–83.
30. D.Bentley, A.M.Young, L.Rowell, et al. Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol. 2012;60(4):390–396.
31. Z.Li, K.Hong, I.Yip, et al. Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program:a retrospective study. Curr Ther Res Clin Exp. 2003;64(7):447–460.
32. Z.Li, M.Maglione, W.Tu, et al. Meta-analysis:pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–546.
33. H.O.Kim, J.A.Lee, H.W.Suh, et al. Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity. Korean J Fam Med. 2013;34(5):298–306.
34. E.J.Hendricks, R.B.Rothman. Phentermine therapy for obesity does not elevate blood pressure. Diabetes Obes Metab. 2011;13(10):963–964.
35. R.B.Rothman, E.J.Hendricks. Phentermine cardiovascular safety. Am J Emerg Med. 2009;27(8):1010–1013.
36. E.J.Hendricks, F.L.Greenway, E.C.Westman, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351–2360.
37. E.A.Thomas, B.McNair, J.L.Bechtell, et al. Greater hunger and less restraint predict weight loss success with phentermine treatment. Obesity (Silver Spring). 2016;24(1):37–43.
38. VIVUS. VIVUS announces issuance of two key U.S. Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029. Press Release 2013 Nov 13.
39. FDA. Risk of oral clefts in children born to mothers taking Topamax (topiramate). FDA Drug Saf Commun. 2011 Mar 4.
40. FDA. NDA 22580 VI-0521 (Qnexa) Briefing Document; 2012 Feb 22.
41. M.H.Davidson, S.Tonstad, S.Oparil, et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index >/=27 kg/m(2). Am J Cardiol. 2013;111(8):1131–1138.
42. W.P.James, I.D.Caterson, W.Coutinho, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.• Long-term study examining the effects of sibutramine on cardiovascular outcomes. This study generated the data for the eventual removal of sibutramine from the US market by the FDA.
43. FDA. Drug details - Belviq. In:FDA approved drug products. 2012.
44. Arena Pharmaceuticals IEI. Arena Pharmaceuticals Issued Additional Patent Covering BELVIQ® (lorcaserin HCl) by United States Patent and Trademark Office. Press Release 2015 Oct 27.
45. S.R.Smith, N.J.Weissman, C.M.Anderson, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256.
46. M.C.Fidler, M.Sanchez, B.Raether, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults:the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
47. N.T.Bello, N.C.Liang. The use of serotonergic drugs to treat obesity–is there any hope? Drug Des Devel Ther. 2011;5:95–109.
48. N.J.Weissman, M.Sanchez, G.G.Koch, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560–567.
49. J.D.Gotthardt, N.T.Bello. Efficacy and safety of lorcaserin-antiobesity effects with benefits. J Symptoms Signs. 2014;3(5):352–357.
50. Arena Pharmaceuticals IEI. U.S.FDA approves Belviq XR, a once-daily formulation of lorcaserin for chronic weight management. Press Release 2016 Jul 19.
51. FDA. FDA approves weight-management drug Contrave. Press Release 2014 Sep 10.
52. Orexigen Therapeutics I. Orexigen(R) Therapeutics Issued a Key U.S. Patent Covering Composition of Contrave(R) into 2025. Press Release 2008 May 27.
53. J.L.Verpeut, N.T.Bello. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf. 2014;13(6):831–841.
54. Takeda Pharmaceuticals I. CONTRAVVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. Deerfield (IL):Orexigen Therapeutics, I; 2014.
55. F.L.Greenway, K.Fujioka, R.A.Plodkowski, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I):a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
56. C.M.Apovian, L.Aronne, D.Rubino, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943.
57. T.A.Wadden, J.P.Foreyt, G.D.Foster, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification:the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.
58. P.Hollander, A.K.Gupta, R.Plodkowski, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
59. S.E.Nissen, K.E.Wolski, L.Prcela, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors:a randomized clinical trial. JAMA. 2016;315(10):990–1004.
60. T.A.Wadden, P.Hollander, S.Klein, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss:the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–1451.
61. Saxenda (liraglutide injection). Prescribing Information. Plainsboro (NJ):Novo Nordisk, I; 2014.
62. Victoza (liraglutide injection). Prescribing Information. Plainsboro (NJ):Novo Nordisk, I; 2014.
63. R.V.Overgaard, K.C.Petri, L.V.Jacobsen, et al. Liraglutide 3.0 mg for weight management:a population pharmacokinetic analysis. Clin Pharmacokinet. 2016 May 19. [Epub ahead of print].
64. X.Pi-Sunyer, A.Astrup, K.Fujioka, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
65. M.J.Davies, R.Bergenstal, B.Bode, et al. Efficacy of Liraglutide for weight loss among patients with Type 2 diabetes:the SCALE diabetes randomized clinical trial. Jama. 2015;314(7):687–699.
66. L.W.Madsen, J.A.Knauf, C.Gotfredsen, et al. GLP-1 receptor agonists and the thyroid:C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153(3):1538–1547.
67. F.Boess, C.Bertinetti-Lapatki, S.Zoffmann, et al. Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. J Mol Endocrinol. 2013;50(3):325–336.
68. S.P.Marso, G.H.Daniels, K.Brown-Frandsen, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–322.•• A long-term cardiovascular outcomes trial for liraglutide dose (1.8 mg/day) in NIDDM patients. Mean follow-up was 3.8 years.
69. K.M.Flegal, D.Kruszon-Moran, M.D.Carroll, et al. Trends in obesity among adults in the United States, 2005 to 2014. Jama. 2016;315(21):2284–2291.
70. R.Khera, M.H.Murad, A.K.Chandar, et al. Association of pharmacological treatments for obesity with weight loss and adverse events:a systematic review and meta-analysis. Jama. 2016;315(22):2424–2434.
71. N.T.Nguyen, S.Vu, E.Kim, et al. Trends in utilization of bariatric surgery, 2009-2012. Surg Endosc. 2016;30(7):2723–2727.
72. A.Philippidis. Eisai Axing 200+ U.S. Employees in Restructuring. GEN News Highlights, 2015 Apr 10.
73. S.Osborne Arena - Q1 sales will make for interesting Q1 conference call. Seeking Alpha, 2016 May 9.
74. S.Osborne. Arena:Belviq sales going bust. Seeking Alpha, 2016 Apr 8.
75. BCC Research. Obesity drugs and therapies:technologies and global markets. 2016.
76. G.A.Bray. A concise review on the therapeutics of obesity. Nutrition. 2000;16(10):953–960.
77. S.Garattini, T.Mennini, R.Samanin. From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann N Y Acad Sci. 1987;499:156–166.
78. H.M.Connolly, J.L.Crary, M.D.McGoon, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588.
79. C.Y.Teramae, H.M.Connolly, M.Grogan, et al. Diet drug-related cardiac valve disease:the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 2000;75(5):456–461.
80. L.Abenhaim, Y.Moride, F.Brenot, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–616.
81. M.Weintraub, P.R.Sundaresan, M.Madan, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51(5):586–594.
82. M.Weintraub, P.R.Sundaresan, B.Schuster, et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther. 1992;51(5):608–614.
83. M.Weintraub, P.R.Sundaresan, B.Schuster, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595–601.
84. M.Weintraub, P.R.Sundaresan, B.Schuster, et al. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther. 1992;51(5):602–607.
85. FDA. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). FDA; 1997 Sep 15.
86. FDA. Meridia (sibutramine):market withdrawal due to risk of serious cardiovascular events. FDA; 2010 Oct 8.
87. FDA. Risk of oral clefts in children born to mothers taking Topamax (topiramate). FDA Drug Saf Commun. 2011 Mar 4.• Statement issued by FDA warning of the birth defects associated with topiramate.
88. C.Leggatt-Cook, K.Chamberlain. Blogging for weight loss:personal accountability, writing selves, and the weight-loss blogosphere. Sociol Health Illn. 2012;34(7):963–977.
89. AMA. American medical association response to “Guidance for Industry:Qualified Health Claims in the Labeling of Coventional Foods and Dietary Supplements [Docket No. 02N-0515]” dockets management branch (HFA-305) FDA. 2003.•• AMA response on FDA and USP policy on the regulation of dietary supplements.
90. J.L.Pillitteri, S.Shiffman, J.M.Rohay, et al. Use of dietary supplements for weight loss in the United States:results of a national survey. Obesity (Silver Spring). 2008;16(4):790–796.
91. Marketdata Enterprises. $65 Billion U.S. weight loss market is in transition. Press Release 2015 Apr 21.
92. S.Smith, E.L.Seeholzer, H.Gullett, et al. Primary care residents’ knowledge, attitudes, self-efficacy, and perceived professional norms regarding obesity, nutrition, and physical activity counseling. J Grad Med Educ. 2015;7(3):388–394.
93. S.B.Prasad, F.Fahrtash, Y.Malaiapan, et al. Prevalence, detection, and management of the metabolic syndrome in patients with acute myocardial infarction:role of an obesity-centric definition. Cardiol Res Pract. 2010; July 27;2010:1–7.
94. A.H.Mokdad, E.S.Ford, B.A.Bowman, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79.
95. Foundation RWJ. The State of Obesity:Medicare and Medicaid Obesity Coverage; 2015. Available from: http://stateofobesity.org/policy/quality-affordable-healthcare-and-obesity/medicare-and-medicaid-obesity-coverage